Present one to two-year follow-up data for AMT-130 cohorts

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 8 Aug 2022
Due: 30 Jun 2023
Delivered: 21 Jun 2023

Deadline
Met
Late
Not met
Today

What the company said

“presentation of one to two-year follow-up on both low and high-dose cohorts in the second quarter of 2023”

SourceuniQure N.V. Form 8-K press release, 2022-08-08
FilingSEC filing index
Deadline as statedsecond quarter of 2023
Deadline used30 Jun 2023, the last day of the stated period
TypeProject
Permanent referenceKI-C-2022-QURE-001810
Cite as https://keptindex.org/c/KI-C-2022-QURE-001810/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced interim clinical data, including up to 24-month follow-up for AMT-130 cohorts, in June 2023, meeting the second-quarter deadline.

A
uniQure N.V. 10-Q filed 2023-08-01 Regulatory filing · published 1 Aug 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC
“On June 21, 2023, we announced interim data, including up to 24-month follow-up, from 26 patients enrolled in the ongoing U.S. Phase I/II clinical trial of AMT-130.” ✓ confirmed on the page

Market reaction: the shares moved -4.9% against the S&P 500 over the three sessions around the disclosure (31 Jul 2023 to 3 Aug 2023). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +550 days
2 versions

Version 1 · original · stated 8 Aug 2022

Deadline 30 Jun 2023 (“second quarter of 2023”)
Version 2 · stated 5 Oct 2023

Deadline 31 Dec 2024 (“2024”) · target 3 years · wording firm

“Also in 2024, the Company will present up to 3-year follow-up data on all patients in the U.S. and European Phase I/II trials”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Present
Deliverable: Follow-up data presentation
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.